4 analysts have shared their evaluations of Jazz Pharmaceuticals (NASDAQ:JAZZ) during the recent three months, expressing a mix of bullish and bearish perspectives.

Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

	Bullish	Somewhat Bullish	Indifferent	Somewhat Bearish	Bearish
Total Ratings	3	1	0	0	0
Last 30D	1	0	0	0	0
1M Ago	0	0	0	0	0
2M Ago	2	0	0	0	0
3M Ago	0	1	0	0	0

Analysts have recently evaluated Jazz Pharmaceuticals and provided 12-month price targets. The average target is $239.75, accompanied by a high estimate of $275.00 and a low estimate of $219.00. This upward trend is apparent, with the current average reflecting a 14.17% increase from the previous average price target of $210.00.

Analyzing Analyst Ratings: A Detailed Breakdown

In examining recent analyst actions, we gain insights into how financial experts perceive Jazz Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst	Analyst Firm	Action Taken	Rating	Current Price Target	Prior Price Target
Jason Gerberry	B of A Securities	Raises	Buy	$275.00	$263.00
Joon Lee	Truist Securities	Raises	Buy	$230.00	$220.00
Ami Fadia	Needham	Raises	Buy	$235.00	$210.00
David Amsellem	Piper Sandler	Raises	Overweight	$219.00	$147.00

Key Insights:

• Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Jazz Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.
• Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Jazz Pharmaceuticals compared to the broader market.
• Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Jazz Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Jazz Pharmaceuticals's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on Jazz Pharmaceuticals analyst ratings.

Delving into Jazz Pharmaceuticals's Background

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Jazz Pharmaceuticals's Economic Impact: An Analysis

Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.

Positive Revenue Trend: Examining Jazz Pharmaceuticals's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.74% as of 30 September, 2025, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 22.33%, the company showcases strong profitability and effective cost control.

Return on Equity (ROE): Jazz Pharmaceuticals's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 6.56%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): Jazz Pharmaceuticals's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.25% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: Jazz Pharmaceuticals's debt-to-equity ratio surpasses industry norms, standing at 1.37. This suggests the company carries a substantial amount of debt, posing potential financial challenges.

Understanding the Relevance of Analyst Ratings

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.

This article was generated by Benzinga's automated content engine and reviewed by an editor.